AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04747704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Principles Counseling
Description: A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
Study NCT03477955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK interspinous spacer
Description: To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
Study NCT02712437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROSPECT
Description: PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
Study NCT00788593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
Study NCT00788593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008) High Dose
Description: EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
Study NCT00788593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008) Low Dose
Description: EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
Study NCT02480231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retropubic Midurethral Sling
Study NCT01606852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
Study NCT03018093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR-011
Description: CD19-targeted chimeric antigen receptor T cells
Study NCT03352752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive
Description: Wearing VR helmet before operation
Study NCT03352752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without HTC Vive
Description: Wearing a blindfold before operation
Study NCT01534637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given PO
Study NCT01534637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01534637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01534637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01534637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01534637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01534637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01534637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy
Description: Receive aprepitant
Study NCT01534637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive aprepitant
Study NCT01922752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37440
Description: CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined.
Study NCT03715322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study NCT03715322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study NCT03715322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
Study NCT03715322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
Study NCT03715322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study NCT03715322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study NCT02322619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Tablets 400 mg
Description: Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
Study NCT02322619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Tablets 400 mg
Description: Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
Study NCT03912402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, IV infusion
Study NCT03912402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT03912402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT03912402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or carboplatin)
Description: IV infusion
Study NCT04757181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The IBD-AID
Description: Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
Study NCT02516384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
Study NCT01145924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS TBNF
Description: Transbronchial needle forceps will be use with the EBUS TBNA scope
Study NCT02582372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and bupivacaine
Description: 10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
Study NCT02582372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and bupivacaine
Description: 25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
Study NCT00805155 — intervention group
Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study NCT04070209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
Study NCT04070209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.
Study NCT02146924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Description: Given IV
Study NCT02146924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV
Study NCT02146924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02146924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01695941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01695941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT01695941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01695941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03416712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening survey and accompanying handout for resources
Description: Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
Study NCT02672722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
Study NCT02672722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02672722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Ultrasound
Description: This done before and after exercise with the help of Definity to see changes in kidney blood flow
Study NCT02825485 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Voiding cystourethrogram
Study NCT04287478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
Study NCT00936507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Density/Portion Size
Study NCT03819816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEA-App
Description: The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility.
Study NCT03819816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Information group
Description: The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
Study NCT01063140 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rabies Vaccine (RabAvert)
Description: The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
Study NCT01063140 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rabies Vaccine (Imovax)
Description: The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
Study NCT01954407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking-Related Messages
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Per day 75mg
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Per day 75mg
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on day 1 every 3 weeks for 2 cycles
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 on day 1 every 3 weeks for 2 cycles
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 mg / m2 on day 1 every 3 weeks for 2 cycles
Study NCT04287894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 6 mg / m2 on day 1 every 3 weeks for 2 cycles
Study NCT04287894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemo radiotherapy
Description: Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Study NCT01881841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cMET
Description: Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
Study NCT05062941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
Study NCT05062941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser therapy (HILT)
Description: HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total.
Study NCT02326207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infant Ventilator Circuit Dual Heated with Autofeed Chamber
Study NCT02326207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infant Ventilator Circuit Dual Heated with Autofeed Chamber
Study NCT02499341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
Study NCT02499341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
Study NCT01848899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: contrast media used during coronary angiography
Study NCT01848899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Description: contrast media used during coronary angiography
Study NCT01848899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: A direct thrombin inhibitor
Study NCT00379197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
Study NCT00379197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
Study NCT05412472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 45 mg IV infusion of GC4419 over 60 minutes.
Study NCT04287894 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemo radiotherapy
Description: Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
Study NCT04287894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: After CIT-CRT
Study NCT03925961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education
Description: The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
Study NCT02199106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left temporal verum cTBS
Description: Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS
Study NCT02199106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left temporal placebo cTBS
Description: Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS
Study NCT01140854 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar spine surgery
Description: (non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
Study NCT00805155 — intervention group
Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study NCT00805155 — intervention group
Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study NCT02448849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Percutaneous injection
Description: percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.